Kernel's revolutionary neuroimaging technology, flow1, validated in published feasibility study on measuring psychedelic effects

Los angeles--(business wire)--kernel, a leader in non-invasive neuroimaging, announces the publication of their study "measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using td-fnirs," in the journal scientific reports from the nature portfolio of journals. the study, sponsored by cybin inc. (neo:cybn) (nyse american:cybn), underscores the ability of kernel's flow1 system to capture and analyze brain changes resulting from the administration of a psych.
CYBN Ratings Summary
CYBN Quant Ranking